Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
U.S. Securities and Exchange Commission v. Cell>Point, LLC et al
Case Number:
1:21-cv-01574
Court:
Nature of Suit:
Securities, Commodities, Exchange
Judge:
Firms
Government Agencies
-
March 04, 2025
Colo. Biotech, Founders Owe SEC $14.3M Over Fraud Claims
A Colorado federal judge has ordered a biotech startup and two of its founders to pay the U.S. Securities and Exchange Commission roughly $14.3 million and barred them from serving as officers and directors of public companies after finding that they fraudulently raised over $10 million by overstating their own investments in the company.
-
May 13, 2024
SEC Says Biotech Co., Atty Should Pay $14M For Investor Lies
Federal securities regulators have said a Colorado biotech startup and two of its founders should pay more than $14 million in ill-gotten profits, including interest, for lying to investors about the company's financial position, arguing that the founders showed a "total disregard" for investors.
-
July 24, 2023
Biotech Co. Can't Defend Fundraising Claims, SEC Says
Federal securities regulators say a Colorado biotech company and its founders intended to dupe investors into giving more when they overstated their own fundraising and personal contributions to the venture by tens of millions of dollars, asking a judge to find the company broke the law.
-
May 10, 2023
Biotech Co. Facing Third Contempt Says It Misread Order
The CEO of a biotech company accused of defrauding its investors tried Wednesday to persuade a Colorado federal judge not to hold him in contempt for a third time, arguing he misunderstood a court order requiring him to disclose alleged securities violations and contempt orders when soliciting money from investors.
-
May 04, 2023
BioTech Co. Must Prove It Didn't Flout Court Order In SEC Suit
A Colorado federal judge has ordered a biotech company accused of defrauding its investors to prove that it didn't, for a third time, violate court orders by failing to notify potential investors of an ongoing U.S. Securities and Exchange Commission action and contempt orders against it.
-
June 11, 2021
SEC Says Biotech Co. Tricked Investors Out Of Millions
The U.S. Securities and Exchange Commission has claimed in a new federal lawsuit that a Colorado-based radiopharmaceutical company misled investors and defrauded them into buying millions of dollars in company securities.